The pharma giant has secured rights to an experimental therapy for celiac disease from Alvine Pharmaceuticals for $70 million in upfront payments and the promise of more money down the road.
Riding the wave of a successful Phase I trial down under and $20 million in VC funding, Massachusetts biotech ImmusanT has launched a clinical trial in the U.S. for Nexvax2, its experimental vaccine to treat celiac disease.
In Sweden, between 1984 and 1996, there was a four-fold increase in cases of celiac disease, and the rates then fell as quickly as they rose. A team of Swedish researchers looked at medical records to unpack whether there really was a cause and effect between changes in the vaccination patterns and the spike in disease.
The former CEO of Alba Therapeutics, Blake Paterson, has put together a $22 million A round to launch his new biotech in Baltimore.
Microtest Laboratories will manufacture Nexvax2 for a mid-stage trial of ImmusanT's vaccine as a treatment for celiac disease. ImmunsanT secured $20 million in venture captial funding from Vatera
ImmusanT has won a big round of venture capital for its work on a vaccine for celiac disease. Vatera Healthcare Partners is putting up $20 million to help support clinical development of Nexvax2. A
After importing the IP for a new therapeutic vaccine that promises to desensitize celiac disease patients to the toxic effects of gluten, the newly established ImmusanT has rounded up $20 million
Sufferers from celiac disease may get a reprieve from their gluten-free diets thanks to a vaccine currently in Phase I trials. But the vaccine won't go into Phase II until next year at the earliest,
A research team at the University of Chicago has made a breakthrough discovery that could pave the way to a new treatment for celiac disease, a painful digestive ailment that afflicts about one in